🍂 Enjoy the Fall Season! 🍂
MindTheDesk

Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease

Gillette Archived • October 8, 2026 • 3 views
SYCUME® Significantly Improved Proptosis (Response Rate 60.4% / LS Mean Change from Baseline -1.88 mm) with Favorable Safety Profile in Participants with Inactive Thyroid Eye Disease(TED)
Source: Gillette News Record | https://www.gillettenewsrecord.com/search/?f=rss&t=article&l=50&s=start_time&sd=desc - Read Original
"Adventure is where you chose to go."

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!

Sponsored
"We build AI or anything ICST"